Evidence map›Paper›PMID 39492683›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2025

Characterization of Incident Interstitial Lung Disease in Late Systemic Sclerosis.

Sabrina Hoa, Claudie Berger, Nouha Lahmek, Maggie Larché, Mohammed Osman, May Choi, Janet Pope, Carter Thorne, Canadian Scleroderma Research Group, Marie Hudson

Abstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Re-envisioning clinical trial design in systemic sclerosis.Expert review of clinical immunology · 2025
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sabrina HoaCentre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Claudie BergerResearch Institute of the McGill University Health Center, Montréal, Québec, Canada.
Nouha LahmekCentre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Maggie LarchéMcMaster University, Hamilton, Ontario, Canada, and University of Calgary, Calgary, Alberta, Canada.
Mohammed OsmanUniversity of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0003-3580-6074
May ChoiUniversity of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-3760-2737
Janet PopeUniversity of Western Ontario, London, Canada.ORCID 0000-0003-1479-5302
Carter ThorneSouthlake Regional Health Centre, Newmarket, Ontario, Canada.
Canadian Scleroderma Research Group
Marie HudsonMcGill University and Lady Davis Institute, Jewish General Hospital, Montréal, Quebec, Canada.

Funding

Fonds de Recherche du Québec en SantéSclérodermie QuebecUniversité de Montréal Scleroderma Chair
6 · The paper itself

Abstract

objectiveInterstitial lung disease (ILD) is a common and potentially lethal complication of systemic sclerosis (SSc). Screening by high-resolution computed tomography (HRCT) is recommended in all patients with risk factors, including early disease. Little is known on late presentations of ILD. This study aimed to characterize the incidence, risk factors, and outcomes of late-onset SSc-ILD.

methodsStudy participants enrolled in the Canadian Scleroderma Research Group cohort from 2004 to 2020 without prevalent ILD were included. Incidence and risk factors for ILD (on HRCT) were compared according to disease duration above (late) and below (earlier) seven years from the first non-Raynaud manifestation. Risk of ILD progression was compared using Kaplan-Meier and multivariable Cox models.

resultsOverall, 199 (21%) of 969 patients developed incident ILD over a median of 2.4 (interquartile range 1.2-4.3) years. The incidence rate in late SSc (3.7/100 person-years) was lower than in earlier SSc (relative risk 0.68, 95% confidence interval [CI] 0.51-0.92). Risk factors for incident ILD included male sex, diffuse subtype, myositis, antitopoisomerase I autoantibodies, and higher C-reactive protein levels. Patients with late-onset ILD were also less frequently White and more frequently had arthritis and anti-RNA-polymerase III autoantibodies. Lung disease severity was similar between late- and earlier-onset SSc-ILD (forced vital capacity 88% and 87%, diffusion capacity of the lungs for carbon monoxide 64% and 62%, respectively). Progression rates were also similar between late- and earlier-onset SSc-ILD (log rank P = 0.8, hazard ratio 1.11, 95% CI 0.58-2.10).

conclusionILD can present in late SSc. Risk factors and progression rates overlapped with earlier-onset SSc-ILD. Surveillance for ILD should continue in longstanding SSc. Frequency and modality of monitoring remain to be defined.

Indexed as

Lung Diseases, InterstitialScleroderma, SystemicAdultAgedCanadaDisease ProgressionFemaleHumansIncidenceMaleMiddle AgedProportional Hazards ModelsRisk FactorsTomography, X-Ray Computed

Identifiers

PMID39492683
PMCPMC11936498

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.